Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. We designed a prospective, double-blind controlled trial to determine predictors of loss of renal function in patients with insulin dependent diabetes and established nephropathy. A total of 409 insulin-dependent diabetic patients with established nephropathy enrolled in a trial on the effect of Captopril on the rate of progression of renal disease. Baseline demographic, clinical (history and physical) and laboratory parameters were analyzed as risk factors for time to progression. Dichotomous characteristics were compared by Fisher's exact test and continuous characteristics with the Wilcoxon rank-sum test. Univariate proportional hazards regression analysis was used to estimate relative risk of nephropathy progression, and bivariate proportional hazard regression to identify interactions with the treatment group assignment. Multivariate proportional hazard regression was employed to determine which characteristics were independent risk factors. We found that a number of demographic and clinical characteristics were significantly associated with nephropathy progression even after adjustment for treatment group. However, after multivariate analysis, the risk factors that independently predicted progression were onset of IDDM later in life, parental diagnosis of IDDM, the presence of edema, increased mean arterial pressure, and an abnormal electrocardiogram. Likewise, a number of laboratory characteristics were also predictive of nephropathy progression. A low hematocrit, high blood sugar, and higher protein excretion predicted nephropathy progression as did a higher serum creatinine, particularly in the face of a normal serum albumin. In conclusion, this study identifies a number of clinical and laboratory risk factors that can predict which patients with insulin-dependent diabetes with established nephropathy are more likely to sustain a clinically important decrease in renal function over a median follow-up of three 
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Diabetic nephropathy is the single most common cause of renal failure leading to enrollment in the Medicare End-Stage Renal Program [1, 2] . A substantial subset of approximately 35 to 40% of insulin dependent diabetics develop nephropathy [3] . Once diabetic nephropathy is established the rate of loss of renal function appears to be extremely variable [4] . There have been several studies that have examined the factors that impact on the risk for the development of nephropathy in diabetic populations; as such, factors that may or may not impact the rate at which renal functional loss ensues once nephropathy is well established by the presence of proteinuria. In small studies, race [7, 8] , hypercholesterolemia [9] , the degree of proteinuria [10] , mean arterial pressure [11, 12] , diuretic use [13] as well as the levels of hemoglobin A1C [14] , angiotensin II and aldosterone [151 have all been identified as potential predictors of progression in such a population. However, there is no large scale study that simultaneously has examined several potential factors in the same population. The clinical trial of angiotensin converting enzyme inhibition with Captopril in 409 patients with insulin-dependent diabetes and diabetic nephropathy demonstrated that assignment to Captopril treatment reduced the risk of progressive renal disease [16] . This patient cohort offers a unique database from which potential predictors of progressive loss of renal function in patients with insulin-dependent diabetes can be identified. In the present study, we systematically analyzed the impact of a large number of baseline characteristics on the loss of renal function in this cohort of subjects with established diabetic nephropathy.
Methods
The study was a prospective, double-blind, randomized clinical trial performed in 30 clinical centers [16] . The study protocol was approved by the institutional review board at each center, and all patients gave written informed consent.
Entty and exclusion criteria
Patients 18 to 49 years of age were eligible if they had insulin-dependent diabetes mellitus for at least seven years, with an onset before the age of 30 years, and had diabetic retinopathy, urinary protein excretion of 500 mg per 24 hours, and a serum creatinine concentration of < 2.5 mg per deciliter (220 jimol per liter). All patients satis'ing these criteria were eligible for the study, regardless of previous blood-pressure status or a previous need for antihypcrtensive medication. Patients who were receiving angiotensin-converting-enzyme inhibitors or calcium channel antagonists were eligible provided their blood pressure could be maintained within the blood-pressure goals required by the trial without these drugs. Therapy with an angiotensin-convertingenzyme inhibitor, other than the coded medication, and calcium channel antagonists were not allowed during the trial. Patients were excluded for the following reasons: pregnancy, a dietary evaluation that indicated marked departure from standard dietary recommendations, white-cell count below 2500 per cubic millimeter, congestive heart failure (New York Heart Association class III or worse), and a serum potassium concentration of 6 mmol per liter.
Eligible patients were stratified according to center and randomly assigned to a group according to a standard urn design. Those assigned to the Captopril group received a dose of 25 mg three times daily, and those assigned to the control group received identical-appearing placebo tablets three times daily.
The patients' diabetes was managed in accord with their historical treatment schedule. Diabetes control was monitored by measurements of glycosylated hemoglobin. After randomization, the patients were seen at two weeks, at one month, and every three months thereafter until they died, required dialysis, or underwent renal transplantation. Compliance in taking the coded medications was determined by the nurse coordinators with the pill-count method. The patients' vital status, need for dialysis, and need for transplantation were monitored until September 30, 1992. Glycosylated hemoglobin, serum creatinine, and 24-hour urinary excretion of creatinine, protein, and urea were measured by the central laboratory at each visit according to standard methods.
Outcomes
The primary study outcome was a doubling of the baseline serum creatinine concentration to at least 2.0 mg per deciliter (177 jmol per liter), confirmed by the central laboratory. Secondary analyses included the length of time to the combined end points of death, dialysis, and transplantation and changes in renal function, assessed in terms of the serum creatinine concentration, 24-hour creatinine clearance, and urinary protein excretion. Other reasons for discontinuing the coded medication were defined for patients whose blood pressure could not be maintained within the limits dictated by the study and those with persistent hyperkalemia (potassium level exceeding 6 mmol per liter), adverse drug effects, pregnancy, or intercurrent illness.
Statistical analysis
Statistical Analysis System software was used for all data management and analysis [17] . Risk factors for time to progression of nephropathy (that is, doubling of baseline serum creatinine concentration to at least 2.0 mg per deciliter) included baseline demographic, clinical (history and physical) and laboratory characteristics. Dichotomous baseline characteristics of the nephropathy progression groups were compared with Fisher's exact test [18] ; continuous baseline characteristics were compared with Wilcoxon rank-sum tests [19] . For each of these baseline characteristics, a univariate proportional hazards regression model was used to estimate the relative risk (that is, hazard rate ratio) of nephropathy progression and corresponding 95% confidence interval; the Wald criterion was used to assess significance of association (all reported P values are two-sided) [20] . To improve the skewness of the baseline distributions of serum glucose and 24-hour urine total protein, values were log-transformed for the proportional hazards regression analysis.
Bivariate proportional hazards regression was used to identify interactions between the treatment group assignment (Captopril or placebo) and each of the baseline characteristics; the Wald criterion was used to assess significance of the treatment group by baseline covariate interaction. The regression models were hierarchical such that whenever an interaction term was included in the model, related lower-order terms were retained regardless of their statistical significance. Multivariate proportional hazards regression analysis was used to simultaneously consider the effects of the treatment group assignment and the baseline demographic, clinical and laboratory characteristics in predicting time to the progression of nephropathy. Separately for the demographic and clinical characteristics, and for the laboratory characteristics, the full regression model was analyzed to develop a reduced model by backward elimination, a sequential model fitting process in which nonsignificant predictors are removed from the model and coefficients for the remaining predictors are recomputed. in the placebo group. The risk of creatinine doubling among participants assigned to Captopril treatment to the risk of creatmine doubling among participants assigned to placebo treatment was reduced by 48.5% [16] .
Demographic and clinical risk factors of nephropathy progression Table 1 presents the key baseline demographic, history and physical examination characteristics in the IDDM participants with nephropathy based on progression (defined by doubling of baseline serum creatinine concentration to at least 2 mgldl during the follow-up period). Increasing age at randomization, AfricanAmerican race, onset of IDDM later in life, a lower percent of life with IDDM, and a parent diagnosed with diabetes were associated with nephropathy progression during a median follow-up period of three years. For the baseline physical examination parameters, progression of nephropathy was associated with presence of peripheral edema, hypertension, and increased mean arterial pressure. Also, an abnormal EKG increased the risk of progression during the follow-up period. Among numerous factors that did not significantly impact progression, were gender and the presence or absence of a sibling with either diabetes alone or diabetic renal disease.
Proportional hazards regression analysis was used to predict nephropathy progression during the follow-up period using each of the baseline characteristics summarized in Table 1 with adjustment for treatment group assignment. As assignment to Captopril treatment itself significantly decreased the progression of renal disease, an analysis of the interaction between treatment group and the listed demographics and clinical characteristics had to be undertaken. There were no significant (P = > 0.20) interactions between the treatment group assignment and any of the baseline demographic and clinical characteristics. Thus, the relative risk of As shown in Figure 1 , after adjustment for treatment group assignment, each of the baseline demographic and clinical characteristics listed in Table I remained significant (P < 0.05) predictors of time to nephropathy progression. The AfricanAmericans had a 3.5-fold increase in risk of nephropathy progression compared to non-African-Americans (95% confidence interval, 1.8 to 6.5). Prominent history and physical examination risk factors included age at onset of IDDM, peripheral edema and mean arterial pressure. The treatment-adjusted relative risks of nephropathy progression were: 1.4 per five years increase in age at IDDM onset; 2.8 for subjects with peripheral edema; and 1.2 per every 5 mm Hg increase in mean arterial pressure. The demographic and clinical characteristics listed in Table I were analyzed simultaneously to determine which characteristics were independent risk factors for nephropathy progression adjusted for treatment group assignment. As shown in Table 2 by multivariate analysis, some of the demographic and clinical baseline characteristics remained as significant (P < 0.01) independent risk factors of nephropathy progression. These include age of onset of IDDM, parental diagnosis of diabetes, peripheral edema, mean arterial pressure, and an abnormal EKG. In this analysis, race no longer is an independent predictor of progression. This is a consequence of the fact that the above-listed risk factors themselves are more prominent in the African-American patients and thereby eliminate race as an independent risk factor. The most prominent risk factor was the presence of edema (adjusted relative risk = 2.21; 95% confidence interval, 1.35 to 3.62). On the other hand, age at randomization, percent of life with IDDM, and Laboratory risk factors of nephropa thy progression Table 3 presents the baseline laboratory measurements in those who did and did not double their serum ereatinine during the follow-up period. Participants who progressed had significantly higher glycosylated hemoglobin, serum creatinine, cholesterol, glucose, uric acid, and 24-hour urine total protein excretion. Low levels of blood hematocrit, serum albumin, 24-hour urine urea nitrogen, and renal clearance of either ereatinine or iothalamate were associated with progression of nephropathy. There were no significant (P 0.10) interactions between the treatment group assignment and each of the baseline laboratory measurements except for serum creatinine (P = 0.024). As shown in Figure 2 , after adjustment for treatment group assignment, each of the baseline laboratory measurements were significant (P < 0.05) predictors of time to nephropathy progression. Because serum creatinine interacted with the treatment group assignment, the relative risk of progression was estimated within each treatment group. For participants assigned to placebo treatment, the risk of nephropathy progression increased by 2.2 for each 0.25 mgldl increase in serum creatinine. Similarly, the risk of nephropathy progression increased by 1.6 for each 0.25 mg/dl increase in serum creatinine for participants treated with Captopril.
The laboratory measurements listed in Table 3 were analyzed simultaneously to determine which measurements were independent risk factors of nephropathy progression adjusted for the treatment group assignment ( Table 4) . As shown in this table, the independent laboratory risk factors of nephropathy progression were blood hematocrit, glucose, serum creatinine, and 24-hour urine protein excretion. The risk of nephropathy progression decreased with increasing blood hematocrit (adjusted relative risk = 0.73 per increase of 4%). Likewise, risk of nephropathy progression increased as the baseline serum creatinine increased. Since there was a strong interaction between serum creatinine and albumin the risk was calculated at two levels of serum albumin. Table 4 (48.5%) [16] . The decline in renal function in patients with insulin-dependent diabetes and established diabetic nephropathy can vary widely [4] . Being able to predict the subset of patients who will have a more rapid decline in renal function and targeting them for specific interventions is important. A variety of baseline characteristics were identified that predicted progression of renal disease in the patients with insulin-dependent diabetes and established diabetic nephropathy. Among the demographic characteristics, an increase in age and African-American race were such predictors. A later onset of diabetes, a shorter percent of life with IDDM, a parental (but not sibling) diagnosis of diabetes, and hypertension were likewise predictors of progression. The longer percent of life with TDDM in those who did not double their serum creatinine (64.5% vs. 58.3%) in those that did may relate to the younger age of onset of disease in this group (12.4 years) versus those that progressed (15.8 years) , since it appears that the time to complications is better defined at puberty rather than onset of diabetesperse [211. Also, the presence of edema, a high mean arterial pressure and a report of an abnormal EKG also imparted a worse prognosis.
When adjusted for baseline renal function these latter two parameters are not independent factors. Among laboratory data, a lower hematocrit, albumin, urea nitrogen excretion, creatinine and an iothalamate clearance also were associated with progression as were a higher glycosylated hemoglobin, serum creatinine, cholesterol, glucose, uric acid, and urinary protein excretion.
Progression of diabetic nephropathy is a multifactorial process. The interrelationship between many risk factors often confounds any attempt to assess the importance of individual risk factors. In examining the baseline demographic variables, few AfricanAmericans were enrolled in this trial in part reflecting the greater prevalence of NIDDM rather than IDDM in this population [7] . African-American race did not remain as an independent risk factor for progressive renal disease since the African-Americans enrolled had a higher mean arterial pressure, peripheral edema and abnormal EKGs. In practical terms, if these other risk factors are more prevalent in the IDDM African-American population as a whole, then African-Americans presenting for medical care of diabetic kidney disease will be more likely to have a rapid progression of renal disease.
Gender did not predict progression in these patients. This is in contrast to reports of a slower rate of progression of renal disease in women with polycystic kidney disease [22] , IgA nephropathy [23] , and membranous glomerulonephritis [24] . In the Modification of Diet and Renal Disease Study, 840 subjects with chronic renal disease due to causes other than IDDM were enrolled.
Females had a slower rate of decline of renal function [251. Taken
together, it appears that in non-diabetic kidney disease gender appears to be predictive of renal outcome. In contrast in the present study, in which half of the subjects were females, no protective effect of female gender was demonstrated. It is of interest that in the Framingham Study, young hypertensive women had less cardiovascular and cerebrovascular risk than men. However, as in the present trial, this was not the case for men and women with diabetes and hypertension who had equal cardiovascular and cerebrovascular risk [26] . It is thus possible that the presence of diabetes itself overcomes any potential benefits of female gender in protecting renal function. Hypertension has been identified as an important risk factor that accelerates the progressive decline in kidney function in diabetic nephropathy [15, 27] . Although the initial reports of hypertension as a poor prognostic factor were in relatively small groups of patients, in a recent cohort of 131 patients with insulin-dependent and non-insulin diabetes a significant and progressive increase in serum creatinine in individuals whose systolic blood pressure remained elevated above 140 mm Hg while on therapy was documented [28] . It was concluded on the basis of this initial analysis of the data that persistent elevation of the blood pressure added significantly to the progressive renal damage. The group with higher blood pressures had significantly faster rates of rise in their serum creatinine. In addition to hypertension marking this group for a more rapid decline of renal function, higher angiotensin II and aldosterone levels were also associated with a faster rate of decline in renal function [281. Also, multiple studies in patients with IDDM and established nephropathy have demonstrated that lowering elevated blood pressures lead to a slower rate of decline of renal function [29, 30] . En the present analysis, it was found that higher mean arterial blood pressures at baseline were associated with an increased risk of progressive renal insufficiency during the follow-up period. The presence or absence of hypertension itself at baseline was a significant predictor of progression, but not independently when mean arterial Measured by the central laboratory; local laboratory determination for other characteristics pressure at baseline was taken into account. A relatively small increase in mean arterial pressure (5 mm Hg) was associated with significant increases in the risk of doubling of serum creatinine. Also, the mean arterial pressure in the group who doubled their serum creatinine during follow-up was relatively low at 109 mm Hg. A similar effect of higher arterial blood pressure as a risk for progression is also found in non-diabetic renal disease [31] . It is of interest that in our study the average mean arterial pressure at baseline in the group who did not double their serum creatinine was 7 mm Hg lower at 102 mm Hg. Blood pressures that on average were only slightly above current JNC-V recommendations were predictive of progressive renal disease [32] . Also, low mean arterial pressures (102 mm Hg) below the JNCV definition of hypertension were predictive of a slower progression. This may be analogous to the Framingham data that found no lower threshold for blood pressure in terms of risk of stroke, the risk simply being proportional to the blood pressure level from the lowest to the highest recorded [33] . Also from the Framingham study, a mean arterial pressure increase of 7.5 mm Hg was associated with a 46% increase in the risk of stroke, a difference similar to the 7 mm Hg difference seen between stable patients and progressors in our trial. Since relatively high baseline mean arterial pressures were predictive of a worse outcome, redefining blood pressure goals in patients with IDDM and established renal disease is necessary.
Peripheral edema and an increased urinary protein excretion were predictors of a greater risk of doubling serum creatinine. It is likely that sufficient protein losses in the urine lead to peripheral edema and account for edema's strong predictive value. There has been evidence to suggest that the degree of proteinuria is a Relative risk marker for worse progression and that decreasing proteinuria is a marker for amelioration of disease processes [34, 35] . Although the data analysis in this paper cannot comment on the potential beneficial effects of decreasing proteinuria, the degree of baseline proteinuria was a clear predictor of renal outcome. Proteinuria confers a similar risk in non-diabetic renal disease [31] . Abnormalities in lipid metabolism frequently accompany renal disease and may be important in the pathogenesis of renal injury. Hypercholesteremia has been demonstrated to cause renal injury in normal rats [36, 37] and altering lipid status has been demonstrated to preserve renal function [38, 39] . While patients who progressed more rapidly had higher cholesterol levels, this parameter did not prove to be an independent predictor. It is unknown whether lowering the cholesterol in these patients would help slow the rate of decline of renal function. Higher blood sugars at baseline were associated with worse renal outcomes. Animal models of diabetes and epidemiologic studies have implicated hyperglycemia in the pathogenesis of long-term complications of diabetes including the development of renal disease [40] [41] [42] . More recently, the Diabetes Control and Complications Trial has demonstrated that intensive insulin therapy delays the onset and slows the progression of diabetic retinopathy [43] . Thus, it is not surprising that baseline blood glucose control would predict renal outcomes in this study.
The entry level of serum ereatinine strongly predicted the rate of renal progression as it does in other entities such as lupus nephritis [44] . It is of particular interest that the enhanced risk was Based on 407 participants having a total of 67 doubling of serum creatinine events with simultaneous adjustment for the laboratory variables listed as well as treatment group assignment (Captopril or placebo). a Because serum creatinine interacted with serum albumin (P 0.009), relative risks were calculated for two values of serum albumin.
particularly marked in subjects with normal albumin. Since there was a strong interaction between these two variables the analysis was performed at two different levels of albumin. Finally, it must be pointed out that in the original analysis of the benefits of Captopril [16] , a 48% risk reduction was noted. In the present multivariate analysis, when adjusted for the laboratory measurements that independently predicted progression, assignment to Captopril had an even greater risk reduction (62%).
In summary, we conclude that a variety of important baseline demographic, clinical and laboratory characteristics help identify a subpopulation of patients with IDDM and established nephropathy who have a marked increase risk of renal disease progression during a median follow-up of three years. These patients should probably be targeted for early aggressive interventions.
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